← FDA DRUG APPROVALS

FDA NDA · NDA011664

DECADRON

Sponsor: MERCK

APPLICATION
NDA011664
TYPE
NDA
ORIGINAL APPROVAL
1958-10-30
LATEST ACTION
2019-05-08
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

DECADRON · ReferenceDiscontinued
DEXAMETHASONE 6MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
DECADRON · ReferenceDiscontinued
DEXAMETHASONE 0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
DECADRON · ReferenceDiscontinued
DEXAMETHASONE 0.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
DECADRON · ReferenceDiscontinued
DEXAMETHASONE 4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
DECADRON · ReferenceDiscontinued
DEXAMETHASONE 1.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
DECADRON · ReferenceDiscontinued
DEXAMETHASONE 0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL

Approval history

2019-05-08Labeling · Supplement 64 · standardLetterAP
2018-04-23Labeling · Supplement 65 · standardLabelAP
2016-07-29Labeling · Supplement 63 · standardLabelAP
2004-05-17Labeling · Supplement 62 · standardReviewAP
2002-06-25Manufacturing (CMC) · Supplement 60 · priorityAP
1999-02-19Manufacturing (CMC) · Supplement 58 · priorityAP
1998-05-14Manufacturing (CMC) · Supplement 55 · priorityAP
1998-02-26Manufacturing (CMC) · Supplement 57 · priorityAP
1996-03-01Manufacturing (CMC) · Supplement 53 · priorityAP
1993-08-25Labeling · Supplement 50 · standardAP
1989-05-16Labeling · Supplement 44AP
1988-05-03Manufacturing (CMC) · Supplement 47 · priorityAP
1985-11-26Labeling · Supplement 45AP
1984-05-03Manufacturing (CMC) · Supplement 41 · priorityAP
1983-05-11Manufacturing (CMC) · Supplement 43 · priorityAP
1983-03-22Manufacturing (CMC) · Supplement 42 · priorityAP
1982-07-30Labeling · Supplement 36AP
1982-07-30Manufacturing (CMC) · Supplement 21 · priorityAP
1982-02-10Manufacturing (CMC) · Supplement 37 · priorityAP
1981-04-01Labeling · Supplement 38AP
1980-04-23Manufacturing (CMC) · Supplement 35 · priorityAP
1980-02-05Manufacturing (CMC) · Supplement 32 · priorityAP
1980-02-04Labeling · Supplement 34AP
1980-02-04Labeling · Supplement 33AP
1979-10-26Manufacturing (CMC) · Supplement 26 · priorityAP
1979-09-24Manufacturing (CMC) · Supplement 30 · priorityAP
1979-08-15Labeling · Supplement 31AP
1979-07-26Labeling · Supplement 28AP
1979-07-26Labeling · Supplement 24AP
1979-07-26Labeling · Supplement 29AP
1979-07-26Labeling · Supplement 27AP
1978-10-11Manufacturing (CMC) · Supplement 25 · priorityAP
1958-10-30Type 1 - New Molecular Entity · Original · priorityAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →